MaxCyte, Inc. MaxCyte, Inc. - MXCR - Grant of Options

MaxCyte

05/03/2019 07:00

RNS Number : 8081R

MaxCyte, Inc.

05 March 2019

 

 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Grant of Options

 

Maryland, USA - 05 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that on 04 March 2019, a total of 729,200 options of common stock in the Company ("Common Stock") were granted to PDMRs who are directors or officers of the Company ("Option Grants"). Details of the Option Grants are given below:

 

Option Grants to PDMRs
Doerfler, Doug
390,200
Holtz, Ron
177,600
Thompson, J. Stark
26,900
Mandell, Art
26,900
Erck, Stan
26,900
Brooke, Will
26,900
Johnston, John
26,900
Douglas, Richard
26,900
Total
729,200

 

Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 04 March 2019, of 177.50 pence.

 

 

The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Names
Doerfler, Doug
Holtz, Ron
Thompson, J. Stark
Mandell, Art
Erck, Stan
Brooke, Will
Johnston, John
Douglas, Richard
2
Reason for the notification
a)
Position/status
Doerfler, Doug - CEO and Director
Holtz, Ron - CFO and Director
Thompson, J. Stark - Non-executive Chairman
Mandell, Art - Non-executive Director
Erck, Stan - Non-executive Director
Brooke, Will - Non-executive Director
Johnston, John - Non-executive Director
Douglas, Richard - Non-executive Director
b)
Initial notification /Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
MaxCyte, Inc.
b)
LEI
54930053YHXULRFCU991
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Grant of Options over Shares of Common Stock
b)
Identification code
US57777K1060
c)
Nature of the transactions
Grant of Options to PDMRs
d)
Price(s) and volume(s)
Doerfler, Doug - 390,200 at an exercise price of 177.50 pence
Holtz, Ron - 177,600 at an exercise price of 177.50 pence
Thompson, J. Stark - 26,900 at an exercise price of 177.50 pence
Mandell, Art - 26,900 at an exercise price of 177.50 pence
Erck, Stan - 26,900 at an exercise price of 177.50 pence
Brooke, Will - 26,900 at an exercise price of 177.50 pence
Johnston, John - 26,900 at an exercise price of 177.50 pence
Douglas, Richard - 26,900 at an exercise price of 177.50 pence
d)
Aggregated information
- Aggregated volume
- Price
n/a
e)
Date of the transactions
04 March 2019
f)
Place of the transaction
Outside a trading venue

 

 

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com

 

MaxCyte
+1 301 944 1660
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer
Nominated Adviser and Broker
Panmure Gordon (UK) Limited
Emma Earl (Corporate Finance)
Freddy Crossley
James Stearns (Corporate Broking)
+44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
+44 (0)20 3709 5700
maxcyte@consilium-comms.com
Mary-Jane Elliott


 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

 

END

 

 

MSCEANDLEDPNEFF